邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

欧洲抗风湿病联盟及美国风湿病学会关于IL-1介导的自身炎症性疾病(CAPS、TRAPS、MKD和DIRA)诊疗指南解读

周煜,  宋红梅

downloadPDF
文章导航 > 协和医学杂志  > 2023 > 优先出版
周煜, 宋红梅. 欧洲抗风湿病联盟及美国风湿病学会关于IL-1介导的自身炎症性疾病(CAPS、TRAPS、MKD和DIRA)诊疗指南解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0043
引用本文: 周煜, 宋红梅. 欧洲抗风湿病联盟及美国风湿病学会关于IL-1介导的自身炎症性疾病(CAPS、TRAPS、MKD和DIRA)诊疗指南解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0043
shu
ZHOU Yu, SONG Hongmei. Interpretation on the 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: CryopyrinAssociated Periodic Syndromes, Tumour Necrosis Factor ReceptorAssociated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0043
Citation: ZHOU Yu, SONG Hongmei. Interpretation on the 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: CryopyrinAssociated Periodic Syndromes, Tumour Necrosis Factor ReceptorAssociated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0043
shu

欧洲抗风湿病联盟及美国风湿病学会关于IL-1介导的自身炎症性疾病(CAPS、TRAPS、MKD和DIRA)诊疗指南解读

doi: 10.12290/xhyxzz.2023-0043

  • 中国医学科学院北京协和医院儿科, 北京 100730

基金项目: 

北京市自然科学基金(L202050)

国家重点研发计划(2021YFC2702001)

北京协和医院中央高水平医院临床科研专项(2022-PUMCH-B-079)

详细信息
    通讯作者:

    宋红梅,E-mail:songhm1021@126.com

  • 中图分类号: R593.2

Interpretation on the 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: CryopyrinAssociated Periodic Syndromes, Tumour Necrosis Factor ReceptorAssociated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist

  • Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730， China

Funds: 

National Key Research and Development Program of China (2021YFC2702001)； National High Level Hospital Clinical Research Funding (2022- PUMCH-B-079)； Beijing Natural Science Foundation (L202050)

    摘要
  • 摘要: 白细胞介素1(interleukin-1, IL-1)介导的自身炎症性疾病是以IL-1生成增多或通路激活为特征的一大类自身炎症性疾病,主要包括家族性地中海热、冷炎素相关周期热综合征、肿瘤坏死因子受体相关周期热综合征、甲羟戊酸激酶缺乏症以及IL-1受体抑制剂缺陷。此类疾病起病早,受累器官广泛,若未经有效治疗,可导致进行性器官损伤、多种并发症甚至死亡。2016年,欧洲抗风湿病联盟已发布针对家族性地中海热的诊疗推荐意见。为提高该类疾病的诊断能力、治疗及长期管理效果,欧洲抗风湿病联盟及美国风湿病学会于2022年共同发布了针对其他4类疾病的诊疗指南。本文将详细介绍该指南要点,以期指导临床实践。
    Abstract: Interleukin-1 mediated autoinflammatory diseases, a large class of autoinflammatory diseases characterized by increased release of interleukin-1 or activation of the interleukin-1 pathway, mainly include familial Mediterranean fever, cryopyrin-associated periodic syndrome, tumor necrosis factor receptor associated periodic syndrome, mevalonate kinase deficiency syndrome and deficiency of the interleukin-1 receptor antagonist. These diseases present in early childhood and affect multiple systems, which, if untreated, may result in progressive organ damage, morbidity and mortality. In 2016, European Alliance of Associations for Rheumatology (EULAR) published recommendations for familial Mediterranean fever. For the latter four types of diseases, EULAR and the American College of Rheumatology developed several points in terms of diagnosis, management and monitoring in 2022. This article aims to introduce the application of these points.
    • HTML全文
    • 参考文献(38)
  • [1] Masters SL, Simon A, Aksentijevich I, et al. Horror autoinflammaticus:the molecular pathophysiology of autoinflammatory disease (*)[J]. Annu Rev Immunol, 2009, 27:621-68.
    [2] Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes:otolaryngologic and audiologic manifestations[J]. Otolaryngol Head Neck Surg, 2011, 145:295-302.
    [3] Dollfus H, Hafner R, Hofmann HM, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome:ocular manifestations in a recently recognized chronic inflammatory disease of childhood[J]. Arch Ophthalmol, 2000, 118:1386-1392.
    [4] Hill SC, Namde M, Dwyer A, et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA)[J]. Pediatr Radiol, 2007, 37:145-152.
    [5] Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes[J]. Arthritis Rheum, 2013, 65:1116-1121.
    [6] Levy R, Gerard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome:a series of 136 patients from the Eurofever Registry[J]. Ann Rheum Dis, 2015, 74:2043-2049.
    [7] Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptorassociated autoinflammatory syndrome (TRAPS) at presentation:a series of 158 cases from the Eurofever/EUROTRAPS international registry[J]. Ann Rheum Dis, 2014, 73:2160-2167.
    [8] Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever[J]. Ann Rheum Dis, 2016, 75:644-651.
    [9] Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases:cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist[J]. Ann Rheum Dis, 2022, 81:907-921.
    [10] Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases:CryopyrinAssociated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Arthritis Rheumatol, 2022, 74:1102- 1121.
    [11] Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)[J]. Ann Rheum Dis, 2017, 76:942-947.
    [12] Zhou Y, Wang W, Zhong L, et al. Clinical and genetic spectrum of 14 cases of NLRP3-associated autoinflammatory disease (NLRP3-AID) in China and a review of the literature[J]. Orphanet J Rare Dis, 2022, 17:214.
    [13] Sobolewska B, Angermair E, Deuter C, et al. NLRP3 A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome:Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms[J]. J Rheumatol, 2016, 43:1101-1106.
    [14] Kilic H, Sahin S, Duman C, et al. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome[J]. Eur J Paediatr Neurol, 2019, 23:466-472.
    [15] Li C, Tan X, Zhang J, et al. Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS)[J]. Sci China Life Sci, 2017, 60:1436-1444.
    [16] Livneh A, Drenth JP, Klasen IS, et al. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome:two diseases with distinct clinical, serologic, and genetic features[J]. J Rheumatol, 1997, 24:1558-1563.
    [17] van der Hilst JCH, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome[J]. Medicine (Baltimore), 2008, 87:301-310.
    [18] Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, et al. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD)[J]. JIMD Rep, 2016, 27:33-38.
    [19] Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist[J]. JCI Insight, 2017, 2:e94838.
    [20] Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes[J]. Am J Hum Genet, 2002, 71:198-203.
    [21] Mcdermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes[J]. Cell, 1999, 97:133-144.
    [22] D'osualdo A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever[J]. Eur J Hum Genet, 2005, 13:314-320.
    [23] Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist[J]. N Engl J Med, 2009, 360:2426-2437.
    [24] Rowczenio DM, Gomes SM, Arostegui JI, et al. Late-Onset CryopyrinAssociated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience[J]. Front Immunol, 2017, 8:1410.
    [25] Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra:a cohort study to determine three- and five-year outcomes[J]. Arthritis Rheum, 2012, 64:2375-2386.
    [26] Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes:results of a 72-week open-label extension study[J]. Clin Ther, 2012, 34:2091- 2103.
    [27] Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With CryopyrinAssociated Periodic Syndrome Ages Five Years and Younger[J]. Arthritis Rheumatol, 2019, 71:1955-1963.
    [28] Piram M, Kone-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes[J]. Ann Rheum Dis, 2014, 73:2168-2173.
    [29] Batchelor HK, Marriott JF. Paediatric pharmacokinetics:key considerations[J]. Br J Clin Pharmacol, 2015, 79:395-404.
    [30] Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency[J]. Ann Rheum Dis, 2011, 70:2155- 2158.
    [31] Grimwood C, Despert V, Jeru I, et al. On-demand treatment with anakinra:a treatment option for selected TRAPS patients[J]. Rheumatology (Oxford), 2015, 54:1749-1751.
    [32] Rodriguez-Smith J, Lin YC, Tsai WL, et al. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease:Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation[J]. Arthritis Rheumatol, 2017, 69:1325-1336.
    [33] Kuemmerle-Deschner JB, Welzel T, Hoertnagel K, et al. New variant in the ILlRN-gene (DIRA) associated with late-onset, CRMO-like presentation[J]. Rheumatology (Oxford), 2020, 59:3259-3263.
    [34] Papa R, Lane T, Minden K, et al. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS:Data from the Eurofever Registry[J]. J Allergy Clin Immunol Pract, 2021, 9:783-991.e4.
    [35] Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome[J]. Arthritis Care Res (Hoboken), 2017, 69:578-586.
    [36] Obici L, Meini A, Cattalini M, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis[J]. Ann Rheum Dis, 2011, 70:1511- 1512.
    [37] Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency:A Series of 114 Cases From the Eurofever Registry[J]. Arthritis Rheumatol, 2016, 68:2795-2805.
    [38] de Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes[J]. N Engl J Med, 2018, 378:1908-1919.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  45
  • HTML全文浏览量:  5
  • PDF下载量:  34
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-01-18
  • 录用日期:  2023-01-31
  • 网络出版日期:  2023-02-16

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！